Beta Bionics, Inc. BBNX
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 35.51M | 32.01M | 27.63M | 32.12M | 27.25M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 35.51M | 32.01M | 27.63M | 32.12M | 27.25M |
| Cost of Revenue | 15.17M | 13.11M | 11.19M | 13.18M | 12.13M |
| Gross Profit | 20.33M | 18.90M | 16.44M | 18.94M | 15.12M |
| SG&A Expenses | 34.97M | 34.24M | 30.35M | 24.94M | 23.97M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 62.11M | 57.59M | 51.90M | 48.25M | 44.30M |
| Operating Income | -26.61M | -25.58M | -24.27M | -16.12M | -17.04M |
| Income Before Tax | -24.35M | -23.40M | -21.90M | -13.47M | -14.21M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -24.35M | -23.40M | -21.90M | -13.47M | -14.21M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.35M | -23.40M | -21.90M | -13.47M | -14.21M |
| EBIT | -26.61M | -25.58M | -24.27M | -16.12M | -17.04M |
| EBITDA | -25.72M | -24.87M | -23.69M | -15.59M | -16.66M |
| EPS Basic | -0.52 | -0.53 | -0.49 | -0.30 | -0.33 |
| Normalized Basic EPS | -0.33 | -0.33 | -0.31 | -0.19 | -0.20 |
| EPS Diluted | -0.52 | -0.53 | -0.49 | -0.30 | -0.33 |
| Normalized Diluted EPS | -0.33 | -0.33 | -0.31 | -0.19 | -0.20 |
| Average Basic Shares Outstanding | 46.54M | 44.55M | 44.44M | 44.19M | 43.63M |
| Average Diluted Shares Outstanding | 46.54M | 44.55M | 44.44M | 44.19M | 43.63M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |